Basir Atefeh
Department of Biology, Faculty of Basic Sciences, Islamic Azad University, Science and Research Branch, Tehran, Iran. Email:
Asian Pac J Cancer Prev. 2019 May 25;20(5):1445-1451. doi: 10.31557/APJCP.2019.20.5.1445.
Purpose: Some variations in the sequence of methionine synthase reductase (MTRR) gene can increase the risk of various cancers such as prostate cancer. The aim of this study was to investigate the association between prostate cancer and the MTRR A66G and C524T gene single nucleotide polymorphisms (SNPs) using an in silico analysis. Methods: In this case-control study, 218 Iranian men, including 108 men with prostate cancer and 110 prostate cancer-free men, were enrolled. The MTRR A66G and C524T genotyping was performed by PCR-RFLP. Some of the bioinformatics tools were employed for the evaluation of polymorphism on the molecular aspects of the MTRR. Results: With regard to the MTRR A66G polymorphism, the genotype AG (OR: 0.85, 95% CI: 0.47-1.54, p= 0.6014), genotype GG (OR: 0.89, 95% CI: 0.42-1.87, p= 0.7512), and allele G (OR: 0.92, 95% CI: 0.63-1.35, p= 0.6686) were not associated with prostate cancer risk. However, the data for C524T SNP showed that the genotype CT was associated with prostate cancer risk (OR: 1.92, 95% CI: 1.06-3.47, p= 0.0308). Further, carriers of the allele T (OR: 1.80, 95% CI: 1.04-3.13, p= 0.0358) were associated with high risk of prostate cancer. In addition, bioinformatics analysis revealed that C524T SNP could affect some molecular aspects of the protein structure, while having no effect on the mRNA structure. Conclusion: The MTRR C524T is a genetic risk factor for prostate cancer; however, the MTRR A66G is not suggested as a suitable biomarker for prostate cancer. To obtain more reliable results, further studies are recommended to use larger sample sizes and investigate the effects of environmental factors.
甲硫氨酸合酶还原酶（MTRR）基因序列的某些变异会增加患前列腺癌等多种癌症的风险。本研究旨在通过计算机分析调查前列腺癌与MTRR A66G和C524T基因单核苷酸多态性（SNP）之间的关联。方法：在这项病例对照研究中，纳入了218名伊朗男性，其中包括108名前列腺癌患者和110名无前列腺癌男性。通过聚合酶链反应-限制性片段长度多态性（PCR-RFLP）进行MTRR A66G和C524T基因分型。使用了一些生物信息学工具来评估MTRR分子层面的多态性。结果：关于MTRR A66G多态性，基因型AG（比值比：0.85，95%置信区间：0.47 - 1.54，p = 0.6014）、基因型GG（比值比：0.89，95%置信区间：0.42 - 1.87，p = 0.7512）和等位基因G（比值比：0.92，95%置信区间：0.63 - 1.35，p = 0.6686）与前列腺癌风险无关。然而，C524T SNP的数据显示基因型CT与前列腺癌风险相关（比值比：1.92，95%置信区间：1.06 - 3.47，p = 0.0308）。此外，等位基因T的携带者（比值比：1.80，95%置信区间：1.04 - 3.13，p = 0.0358）与前列腺癌高风险相关。另外，生物信息学分析表明C524T SNP可能会影响蛋白质结构的一些分子层面，但对mRNA结构没有影响。结论：MTRR C524T是前列腺癌的一个遗传风险因素；然而，MTRR A66G不被建议作为前列腺癌的合适生物标志物。为获得更可靠的结果，建议进一步研究使用更大样本量并调查环境因素的影响。
